


# Expectations of cost containment measures in the US


In May 2020, we conducted a syndicated study to assess the impact of COVID-19 on biopharmaceutical market access with payers and advisors in the US, Europe, Brazil, and China. Our questions covered vaccines and therapies, both COVID-19 specific and others

Sample	MCOs	PBMs	Medicaid	Providers	Total
	12	4	2	12	30




Here is a snapshot of US payers' and providers' expectations regarding the potential for new cost containment measures to be introduced

## Majority expect some level of cost containment measures to be introduced

### Likelihood of introduction of new cost containment measures



#### Despite short term gains, majority of payers expect longer term need to balance costs:

-  Modest increase in member premiums of commercial plans
-  No change to co-pays or coinsurance
-  Rising unemployment rates will translate to more patients moving onto Medicaid

#### Other suggestions:

-  New plans with higher deductibles and lower out of pocket costs offered for people with low healthcare utilization
-  More restricted formularies and networks for current premiums

Data based on interim sample of n=26



If this study is potentially of interest to your company and you would like to receive a more detailed overview of the results, including individual insights by market, please contact us:

[info@researchpartnership.com](mailto:info@researchpartnership.com) | [researchpartnership.com](http://researchpartnership.com)